Skip to content
Screener

Septerna, Inc. SEPN EBITDA margin

EBITDA margin at other companies

Amgen logo
AmgenAMGN
42.2%+3.0pp
Stoke Therapeutics, Inc. logo
Stoke Therapeutics, Inc.STOK
-572.1%-593pp
Nurix Therapeutics, Inc. logo
Nurix Therapeutics, Inc.NRIX
-427.3%+42.6pp
Schrodinger logo
SchrodingerSDGR
-57%-12.2pp
Rigel Pharmaceuticals logo
Rigel PharmaceuticalsRIGL
42.4%+19.5pp

Other financials

Income statement

See full
Revenue$26.5M+12,011%
Operating income-$13.3M+48.7%
Net income-$8.6M+59.8%
EPS (diluted)-$0.19+61.2%

Balance sheet

See full
Cash & equivalents$71.6M-65.9%
Total debt$23.1M-7.7%
Total equity$378.5M+195%
Total assets$569.7M+31.3%

Cash flow

See full
Operating cash flow-$25.6M-9.8%
CapEx$832.0K+118%
Free cash flow-$26.5M-11.5%

Valuation

See full
Market cap$1.78B+240%
Enterprise value$1.73B+383%
P/S24.7×-696×

Profitability

See full
Operating margin-77.1%-38.4pp
Net margin-49.9%-24.9pp
FCF margin467.9%+243pp

Returns & leverage

See full
Return on equity-12.2%
Debt / equity0.1×
Current ratio4.7×-27.5×

Where this comes from

Calculated from Septerna, Inc.’s reported figures.

Based on trailing twelve months.

The source filing: Septerna, Inc.’s 10-Q, filed May 11, 2026. Open the filing →

Filed
May 11, 2026, 4:08 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001193125-26-216759

FAQ

What is Septerna, Inc.'s EBITDA margin?
Septerna, Inc. (SEPN) reported EBITDA margin of -74.8% in Q1 2026.
How has Septerna, Inc.'s EBITDA margin changed year-over-year?
Septerna, Inc.'s EBITDA margin increased by 99.2% year-over-year, from -9,187.4% to -74.8%.
What does EBITDA margin mean?
EBITDA (earnings before interest, taxes, depreciation, and amortization) as a percentage of revenue, trailing twelve months. A proxy for cash operating profitability that strips out capital-structure and non-cash charges.

Ask your AI about Septerna, Inc.'s ebitda margin.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude